What is BBIO's market cap?

$15.17B, based on the Nov 4 close of $77.89.

Does BridgeBio Pharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of BBIO is sold short?

20.0M shares, 12.5% of float, as of Oct 15, 2026.

What sector is BBIO in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · BBIOHealthcarePharmaceuticals

BridgeBio Pharma, Inc. Common Stock (BBIO)

$77.89+5.21%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$76.83▲ 23.96% in range

Nov 3, 2025Low $61.37 · High $90.17Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

BridgeBio Pharma closed at $77.89 on Nov 4, up 5.21%, 13.6% below its 52-week closing high. Volume of 5.6M shares was 1.99× its 20-day average (above normal).

Split-adjusted performance: +16.3% over one month, +14.4% over six months, +25.7% over one year.

In the quarter ended Sep 30, 2026, revenue was $353.17M, up 192.6% from a year earlier, with a net margin of -23.5%.

Short interest was 20.0M shares at the Oct 15 settlement, up 1.7% from the prior report (12.5% of float, 7.7 days to cover).

Market cap$15.17B194.8M shares

Revenue · quarter$353.2M+192.6% YoY

Diluted EPS$-0.42—

P/E · TTM—P/S 16.0×

Net margin-23.5%Gross 94.2%

Dividend yieldNone

52-week range61.37 – 90.17−13.6% from high

Volume5.6M1.99× 20-day avg

Volatility · 60d34.1%Annualised

Short % of float12.5%7.7 days to cover

Net cash-$938.6MCash $1.54B

Next earnings—Not scheduled

Split-adjusted performance

1W +10.0%1M +16.3%3M −5.9%6M +14.4%YTD +1.8%1Y +25.7%3Y +205.3%5Y +59.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum79

Revenue growth89

Net margin54

Value (low P/E)—

Size96

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short20.0M+1.7% vs prior

Days to cover7.7Settled Oct 15

% of float12.5%

Short vol. 10d54.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
BBIOBridgeBio Pharma	$77.89	+5.21%	+14.4%	+192.6%	−23.5%	—	$15.17B
JAZZJazz Pharmaceuticals	$234.66	+2.14%	+2.7%	+10.4%	−38.9%	74.0	$15.23B	Compare
SMMTSummit Therapeutics	$16.17	+2.34%	−9.4%	—	—	—	$12.90B	Compare
ELANElanco Animal Health Incorporated	$25.31	+3.01%	−3.3%	+10.2%	3.9%	—	$12.65B	Compare
BMRNBioMarin Pharmaceuticals	$57.13	+2.64%	+4.6%	+19.9%	4.5%	151.5	$11.06B	Compare
ALNYAlnylam Pharmaceuticals	$161.08	+0.74%	−46.8%	+16.7%	148.6%	7.9	$21.57B	Compare
VTRSViatris	$19.22	+1.59%	+20.5%	+4.9%	−3.2%	—	$22.08B	Compare
INSMInsmed	$110.00	+5.32%	−19.8%	+268.4%	−19.1%	—	$24.13B	Compare
TGTXTG Therapeutics	$61.63	+1.45%	+46.8%	+70.3%	3.2%	21.4	$9.43B	Compare

News about BridgeBio Pharma

All news →

Should You Invest $1,000 in BridgeBio Pharma Right Now?The Motley Fool · 2d ago▲ Positive Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health RecordsGlobeNewswire Inc. · Oct 11, 2026▲ Positive Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1GlobeNewswire Inc. · Oct 11, 2026▲ Positive FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingZacks Investment Research · Oct 7, 2026▲ Positive BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for AmericansGlobeNewswire Inc. · Aug 31, 2026▲ Positive

Quick answers

What does BridgeBio Pharma do?: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.
What is BBIO's market cap?: $15.17B, based on the Nov 4 close of $77.89.
Does BridgeBio Pharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of BBIO is sold short?: 20.0M shares, 12.5% of float, as of Oct 15, 2026.
What sector is BBIO in?: Healthcare, in the Pharmaceuticals industry.

About BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

HQ: Palo Alto, CA839 employeesListed Jun 27, 2019bridgebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology